Cargando…
Identification of cell type–specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors
Increased MAPK signaling is a hallmark of various cancers and is a central regulator of cell survival. Direct ERK1/2 inhibition is considered a promising approach to avoid ERK1/2 reactivation caused by upstream kinases BRAF, MEK1/2, and KRAS, as well as by receptor tyrosine kinase inhibitors, but th...
Autores principales: | Lebedev, Timofey D., Khabusheva, Elmira R., Mareeva, Sofia R., Ivanenko, Karina A., Morozov, Alexey V., Spirin, Pavel V., Rubtsov, Petr M., Snezhkina, Anastasiya V., Kudryavtseva, Anna V., Sorokin, Maxim I., Buzdin, Anton A., Prassolov, Vladimir S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358475/ https://www.ncbi.nlm.nih.gov/pubmed/35787369 http://dx.doi.org/10.1016/j.jbc.2022.102226 |
Ejemplares similares
-
Subtype of Neuroblastoma Cells with High KIT Expression Are Dependent on KIT and Its Knockdown Induces Compensatory Activation of Pro-Survival Signaling
por: Lebedev, Timofey, et al.
Publicado: (2022) -
MGL S3 Chimeric Enzyme Drives Apoptotic Death of EGFR-Dependent Cancer Cells through ERK Downregulation
por: Bondarev, Nikolay, et al.
Publicado: (2022) -
Synergistic suppression of t(8;21)-positive leukemia cell growth by combining oridonin and MAPK1/ERK2 inhibitors
por: Spirin, Pavel, et al.
Publicado: (2017) -
Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes
por: Lebedev, Timofey, et al.
Publicado: (2021) -
Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs
por: Vagapova, Elmira, et al.
Publicado: (2021)